Eli Lilly and Stock Forecast for 2023 - 2025 - 2030

Updated on 02/01/2023

Stock Rating
16
Price Target
$400.00
Consensus
Outperform
Upside
16.23%
Analysts
12
Stock Rating
16
Upside
16.23%
Analysts
12
Price Target
$400.00

Eli Lilly and Stock Forecast and Price Target

Based on the current earnings figures, this year's price targets for Eli Lilly and were recently set by twelve distinguished experts, with an average mark of $400.00. If it reached this goal, it would represent a potential upside of approximately 16.23% from the previous closing price in January, 2023. The high end is $440.00, and the low is $202.00. If you're looking for information on Eli Lilly and stock, consider checking out the forecasts for comparable firms such as NasdaqGS:AMGN.

$400.00

16.23% Upside

Outperform
Outperform

Eli Lilly and Fair Value Forecast for 2023 - 2025 - 2030

Eli Lilly and's Price has seen growth In the last two years, going from $128.65 to $173.81 – a gain of 35.10% In the next year, analysts believe that Fair Value will reach $205.97 – an increase of 18.50%. For the next eight years, the forecast is forFair Value to grow by 148.04%.

2023 Fair Value Forecast
$205.97
2024 Fair Value Forecast
$250.06
2025 Fair Value Forecast
$302.89
2026 Fair Value Forecast
$342.72
2027 Fair Value Forecast
$362.53
2028 Fair Value Forecast
$395.97
2029 Fair Value Forecast
$413.01
2030 Fair Value Forecast
$431.11
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
JNJ Stock Forecast Johnson & Johnson Outperform 11
$163.42 $181.05 10.45%
ABBV Stock Forecast AbbVie Outperform 10
$147.74 $162.12 11.68%
ROG Stock Forecast Roche Holding Outperform 5
CHF293.60 CHF384.23 24.32%
AZN Stock Forecast AstraZeneca PLC Outperform 8
£10.59k £153.20 -98.53%
NOVN Stock Forecast Novartis Hold 10
CHF85.77 CHF103.75 9.89%

Eli Lilly and Revenue Forecast for 2023 - 2025 - 2030

Eli Lilly and's Revenue has seen growth In the last two years, going from $22.32B to $28.32B – a gain of 26.88% In the next year, analysts believe that Revenue will reach $30.45B – an increase of 7.54%. For the next eight years, the forecast is forRevenue to grow by 69.31%.

2023 Rev Forecast
$30.45B
2024 Rev Forecast
$34.27B
2025 Rev Forecast
$38.90B
2026 Rev Forecast
$42.26B
2027 Rev Forecast
$43.57B
2028 Rev Forecast
$45.83B
2029 Rev Forecast
$47.19B
2030 Rev Forecast
$47.95B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
TMO Stock Forecast Thermo Fisher Scientific Inc Outperform 10
$570.33 $618.99 8.71%
ABT Stock Forecast Abbott Laboratories Outperform 10
$110.55 $116.63 13.07%
AMGN Stock Forecast Amgen Inc Hold 7
$271.73 $268.00 2.31%

Eli Lilly and Dividend per Share Forecast for 2023 - 2025 - 2030

In the last two years, Dividend per Share for Eli Lilly and has grown by 31.78%, going from $2.58 to $3.40. In the coming year, analysts are expecting an increase in Dividend per Share, predicting it will reach $4.20 – an increase of 23.53%. Over the next eight years, experts anticipate that Dividend per Share growth for Eli Lilly and will be 252.65%.

2023 DPS Forecast
$4.20
2024 DPS Forecast
$4.68
2025 DPS Forecast
$5.34
2026 DPS Forecast
$5.47
2027 DPS Forecast
$7.88
2028 DPS Forecast
$9.07
2029 DPS Forecast
$10.43
2030 DPS Forecast
$11.99
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
SAN Stock Forecast Sanofi Outperform 10
91.12€ 108.44€ 20.72%
CSL Stock Forecast CSL Outperform 8
$301.85 $218.60 -25.11%
MRK Stock Forecast MERCK Kommanditgesellschaft au... Outperform 10
191.05€ 209.03€ 9.92%

Eli Lilly and Free Cash Flow Forecast for 2023 - 2025 - 2030

In the last two years, Eli Lilly and's Free Cash Flow has increased by 56.49%, going from $3.80B to $5.95B. In the next year, analysts are expecting an increase in Free Cash Flow, predicting it will reach $8.00B – an increase of 34.52%. The Eli Lilly and forecast is for Free Cash Flow to reach $15.12B or grow by 154.09%.

2023 FCF Forecast
$8.00B
2024 FCF Forecast
$9.32B
2025 FCF Forecast
$10.94B
2026 FCF Forecast
$12.77B
2027 FCF Forecast
$14.28B
2028 FCF Forecast
$14.82B
2029 FCF Forecast
$15.14B
2030 FCF Forecast
$15.12B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
BDX Stock Forecast Becton, Dickinson and Outperform 17
$252.22 $268.00 9.03%
GSK Stock Forecast GSK Hold 16
£1.42k £16.95 -98.87%
ZTS Stock Forecast Zoetis Buy 18
$165.49 $207.87 23.87%

Eli Lilly and Net Income Forecast for 2023 - 2025 - 2030

In the last two years, Eli Lilly and's Net Income has decreased from $8.32B to $5.58B – a 32.90% drop. In the next year, analysts predict that Net Income will reach $8.82B – an increase of 58.00%. For the next eight years, the forecast is for Net Income to grow by 211.18%.

2023 NI Forecast
$8.82B
2024 NI Forecast
$10.57B
2025 NI Forecast
$12.76B
2026 NI Forecast
$13.95B
2027 NI Forecast
$15.07B
2028 NI Forecast
$16.01B
2029 NI Forecast
$16.68B
2030 NI Forecast
$17.37B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
BAYN Stock Forecast Bayer Outperform 7
57.00€ 74.54€ 32.46%
4502 Stock Forecast Takeda Pharmaceutical Company Outperform 16
¥4.08k ¥0.00 7.84%
4519 Stock Forecast Chugai Pharmaceutical Hold 18
¥3.31k ¥0.00 36.03%

Eli Lilly and EBITDA Forecast for 2023 - 2025 - 2030

In the last two years, Eli Lilly and's EBITDA has grown, increasing from $7.23B to $9.73B – an increase of 34.47%. For next year, the 13 analysts predict EBITDA of $11.82B, which would mean an increase of 21.49%. Over the next eight years, the pros' prediction is EBITDAof $20.45B, which would mean a eight-year growth forecast of 110.29%.

2023 EBITDA Forecast
$11.82B
2024 EBITDA Forecast
$14.01B
2025 EBITDA Forecast
$17.51B
2026 EBITDA Forecast
$16.01B
2027 EBITDA Forecast
$17.17B
2028 EBITDA Forecast
$17.93B
2029 EBITDA Forecast
$18.95B
2030 EBITDA Forecast
$20.45B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
ALNY Stock Forecast Alnylam Pharmaceuticals Outperform 7
$226.40 $244.18 10.87%
4503 Stock Forecast Astellas Pharma Outperform 18
¥1.92k ¥0.00 24.74%
BAX Stock Forecast Baxter International Outperform 17
$45.69 $62.83 26.94%

Eli Lilly and EBIT Forecast for 2023 - 2025 - 2030

Eli Lilly and's EBIT has increased by 36.31% In the last two years, going from $6.00B to $8.18B. In the next year, analysts expect EBIT to reach $10.24B – an increase of 25.18%. For the next eight years, the forecast is for EBIT to grow by 143.31%.

2023 EBIT Forecast
$10.24B
2024 EBIT Forecast
$12.44B
2025 EBIT Forecast
$15.21B
2026 EBIT Forecast
$16.48B
2027 EBIT Forecast
$18.00B
2028 EBIT Forecast
$19.05B
2029 EBIT Forecast
$19.75B
2030 EBIT Forecast
$19.90B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
4523 Stock Forecast Eisai Hold 18
¥8.15k ¥0.00 -18.99%
DGX Stock Forecast Quest Diagnostics Hold 10
$148.48 $147.77 -2.68%
4507 Stock Forecast Shionogi & Outperform 18
¥6.44k ¥0.00 36.38%

Eli Lilly and EPS Price Prediction Forecast for 2023 - 2025 - 2030

Eli Lilly and's EPS has seen growth In the last two years, going from $6.04 to $8.16 – a gain of 35.10% In the next year, analysts believe that EPS will reach $9.67 – an increase of 18.50%. For the next eight years, the forecast is forEPS to grow by 148.04%.

2023 EPS Forecast
$9.67
2024 EPS Forecast
$11.74
2025 EPS Forecast
$14.22
2026 EPS Forecast
$16.09
2027 EPS Forecast
$17.02
2028 EPS Forecast
$18.59
2029 EPS Forecast
$19.39
2030 EPS Forecast
$20.24
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
FME Stock Forecast Fresenius Medical Care AG & Co... Hold 18
34.39€ 42.10€ -6.95%
BIM Stock Forecast bioMérieux Outperform 18
96.70€ 105.55€ 11.17%
IPN Stock Forecast Ipsen Hold 17
102.20€ 110.44€ 5.68%